Broad Institute Comprehensive Screening Center

世纪的生物医学研究人员在理解人类疾病的爆炸中心工作。相关基因组的完整序列，如人类和各种传染性生物体，为下一步探索疾病的分子机制奠定了基础。布罗德研究所的研究人员在这场革命的早期阶段就认识到，小分子表型变化背后的细胞通路的扰动将使解剖细胞电路和疾病生物学成为可能，从而为纠正人类疾病开辟了一条道路。在过去的十年里，我们在开放的数据共享环境中以生产模式运营了一个筛选设施，创建了第一个全面的公共小分子数据库和分析环境，其中包含超过2000万个结合和分析井测量，一个新颖的化学生物学信息模型和许多强大的分析工具，并在2007年在人员，筛选自动化，LIMS和机器人技术大大提高了这些已经显着的生产能力。该筛选设施位于一个丰富的环境中，专注于小分子和与疾病生物学和基因组生物学相结合的小分子筛选。我们在这里提出了一个计划，在哈佛和麻省理工学院（BCSC）的广泛研究所经营的综合筛查中心，利用和补充现有的组织和基础设施的举措，与更广泛的MLPCN研究社区合作。

Biomedical researchers in the 21st century work in the epicenter of an explosion in the understanding of human disease. The complete sequences of relevant genomes, like the human and various infectious organisms, lay the foundation for the next steps in probing molecular mechanisms of disease. Broad Institute researchers recognized at an early stage of this revolution that the perturbation of the cellular pathways that underlie phenotypic changes with small molecules will make it possible to dissect cell circuitry and disease biology, thus enabling a path forward to correcting human diseases. We have operated a Screening Facility in a production mode over the past ten years in an open data-sharing environment, created the first comprehensive and public small-molecule database and analysis environment containing over 20 million binding and assay-well measurements, a novel chemical biology information model and many powerful analysis tools, and, in 2007, made a substantial investment in personnel, screening automation, LIMS and robotics that has substantially increased these already significant production capabilities. This screening facility resides within a rich environment focused on small molecules and small-molecule screening integrated with disease biology and genome biology. We propose here a plan to operate a Comprehensive Screening Center at the Broad Institute of Harvard and MIT (BCSC), leveraging and complementing existing organizational and infrastructure initiatives by collaborating with a wider MLPCN research community.